全文获取类型
收费全文 | 14390篇 |
免费 | 1150篇 |
国内免费 | 36篇 |
专业分类
耳鼻咽喉 | 99篇 |
儿科学 | 501篇 |
妇产科学 | 306篇 |
基础医学 | 2041篇 |
口腔科学 | 101篇 |
临床医学 | 1913篇 |
内科学 | 2954篇 |
皮肤病学 | 225篇 |
神经病学 | 1408篇 |
特种医学 | 318篇 |
外科学 | 1570篇 |
综合类 | 156篇 |
一般理论 | 20篇 |
预防医学 | 1746篇 |
眼科学 | 165篇 |
药学 | 984篇 |
中国医学 | 16篇 |
肿瘤学 | 1053篇 |
出版年
2024年 | 28篇 |
2023年 | 238篇 |
2022年 | 290篇 |
2021年 | 577篇 |
2020年 | 375篇 |
2019年 | 631篇 |
2018年 | 620篇 |
2017年 | 417篇 |
2016年 | 462篇 |
2015年 | 463篇 |
2014年 | 571篇 |
2013年 | 831篇 |
2012年 | 1238篇 |
2011年 | 1228篇 |
2010年 | 605篇 |
2009年 | 548篇 |
2008年 | 855篇 |
2007年 | 899篇 |
2006年 | 876篇 |
2005年 | 797篇 |
2004年 | 662篇 |
2003年 | 631篇 |
2002年 | 599篇 |
2001年 | 91篇 |
2000年 | 76篇 |
1999年 | 91篇 |
1998年 | 102篇 |
1997年 | 105篇 |
1996年 | 76篇 |
1995年 | 73篇 |
1994年 | 47篇 |
1993年 | 51篇 |
1992年 | 42篇 |
1991年 | 34篇 |
1990年 | 28篇 |
1989年 | 22篇 |
1988年 | 20篇 |
1987年 | 23篇 |
1986年 | 18篇 |
1985年 | 10篇 |
1984年 | 19篇 |
1983年 | 23篇 |
1982年 | 22篇 |
1981年 | 29篇 |
1980年 | 14篇 |
1979年 | 9篇 |
1978年 | 13篇 |
1977年 | 28篇 |
1976年 | 17篇 |
1974年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
The purpose of this study was to evaluate the outcome of patients with bilateral breast cancer as compared to unilateral breast cancer treated with breast conservation therapy. Sixty patients with bilateral breast cancer (BBC) and 1,080 unilateral breast cancer (UBC) patients treated with breast conservation therapy from 1977 to 1994 were analyzed for outcome. Of the 60 bilateral patients, 44 were metachronous bilateral breast cancer patients (MBBC) and 16 were synchronous bilateral breast cancer patients (SBBC). The majority of patients received lumpectomy, axillary node dissection, and localized radiation therapy. Median tumor size was 1.4 cm for BBC and 1.5 cm for UBC patients. Median total dose to the tumor bed was 60 Gy for both unilateral and bilateral patients. Of the 44 MBBC patients, 14 received breast conservation for both the first and second lesions, while 30 received breast conservation for only the second metachronous lesion. Thus 58 lesions in 44 patients were treated with breast conservation therapy. Of the SBBC patients, 13 of 16 patients received breast-conserving therapy for both breasts, while 3 received a mastectomy for the second synchronous primary. Median follow-up was 50 months for SBBC patients, 45 months for MBBC patients, and 52 months for UBC patients. Local control and survival were analyzed in patients with SBBC, MBBC, and UBC. The interval to development of local recurrence and survival were calculated from the time of development of the second breast lesion in patients with MBBC. No differences were found for survival and failure-free survival in patients with SBBC, MBBC, or UBC. Five-year overall survival by lifetable analysis was 76% for SBBC, 78% for MBBC, and 87% for UBC patients (p = 0.32 by log-rank analysis). The 5-year failure-free survival was 79% for SBBC, 73% for MBBC, and 85% for UBC patients (p = 0.28 by log-rank analysis). No significant differences were seen for median age, tumor size, pathologic node status, tamoxifen use, chemotherapy use, or median total radiation dose for SBBC, MBBC, or UBC patients. A significant difference was found in the incidence of family history of breast cancer in patients with unilateral versus bilateral breast cancer (p = 0.028 by chi-square analysis). However, there was no difference in outcome of patients by family history of breast cancer. The local control was identical in both BBC and UBC patients, with a local failure rate of 3%. Therefore, breast conservation therapy in local-regional, early stage breast cancer is a rational and efficacious treatment modality for patients with SBBC, MBBC, and UBC. 相似文献
992.
Keh CE Shen JM Hahn B Hallahan CW Rehm CA Thaker V Wynne SM Davey RT Lane HC Sereti I 《AIDS (London, England)》2006,20(3):361-369
BACKGROUND: Intermittent administration of interleukin (IL)-2 to HIV infected patients leads to CD4 T-cell expansions that are associated with decreased CD4 T-cell turnover. IL-2 is under evaluation in antiretroviral therapy (ART) interruption studies, but it is unclear how the emergence of viremia may affect CD4 expansions. METHODS: CD4 T-cell responses were evaluated in 27 HIV infected patients on long-term intermittent IL-2 therapy who underwent ART interruption immediately after an IL-2 cycle ('IL-2/off') and compared with responses from a previous IL-2 cycle while on continuous ART ('IL-2/on'). Immunophenotypic analysis, including intracellular Ki67 staining, of cryopreserved peripheral blood mononuclear cells was performed. RESULTS: CD4 T-cell increases, in naive and central memory CD4 T-cell subsets, were observed in the IL-2/on (106 and 327 cells/microl, respectively) and IL-2/off (84 and 184 cells/microl, respectively) cycles 1 month following IL-2 administration. These increases were greater during the IL-2/on cycle (P = 0.05, P = 0.01, respectively). In both cycles, the change in CD4 T-cell count correlated with the change in CD4/CD25 T cells. In the IL-2/off cycle, the change in the proportion of CD4 T cells expressing Ki67 was associated with both the changes in viral load (r = 0.64, P = 0.001) and the changes in CD4 T cells (r = -0.56, P = 0.01). CONCLUSIONS: IL-2 administration followed by ART interruption led to significant, although blunted, CD4 T-cell increases. IL-2 induced CD4 T-cell increases in the setting of emergent viremia were associated with decreased CD4 T-cell activation that counteracted the viremia-induced increases in CD4 T-cell activation. 相似文献
993.
Christelle Dufour Stephanie Foulon Anne Geoffray Julien Masliah-Planchon Dominique Figarella-Branger Valerie Bernier-Chastagner Laetitia Padovani La Guerrini-Rousseau Cecile Faure-Conter Celine Icher Anne-Isabelle Bertozzi Pierre Leblond Tasnime Akbaraly Franck Bourdeaut Nicolas Andr Celine Chapp Pascale Schneider Emilie De Carli Pascal Chastagner Claire Berger Julien Lejeune Christine Soler Natacha Entz-Werl Marie-Bernadette Delisle 《Neuro-oncology》2021,23(7):1163
BackgroundHigh-risk medulloblastoma is defined by the presence of metastatic disease and/or incomplete resection and/or unfavorable histopathology and/or tumors with MYC amplification. We aimed to assess the 3-year progression-free survival (PFS) and define the molecular characteristics associated with PFS in patients aged 5–19 years with newly diagnosed high-risk medulloblastoma treated according to the phase II trial PNET HR+5.MethodsAll children received postoperative induction chemotherapy (etoposide and carboplatin), followed by 2 high-dose thiotepa courses (600 mg/m2) with hematological stem cell support. At the latest 45 days after the last stem cell rescue, patients received risk-adapted craniospinal radiation therapy. Maintenance treatment with temozolomide was planned to start between 1–3 months after the end of radiotherapy. The primary endpoint was PFS. Outcome and safety analyses were per protocol (all patients who received at least one dose of induction chemotherapy).ResultsFifty-one patients (median age, 8 y; range, 5–19) were enrolled. The median follow-up was 7.1 years (range: 3.4–9.0). The 3 and 5-year PFS with their 95% confidence intervals (95% CI) were 78% (65–88) and 76% (63–86), and the 3 and 5-year OS were 84% (72–92) and 76% (63–86), respectively. Medulloblastoma subtype was a statistically significant prognostic factor (P-value = 0.039) with large-cell/anaplastic being of worse prognosis, as well as a molecular subgroup (P-value = 0.012) with sonic hedgehog (SHH) and group 3 being of worse prognosis than wingless (WNT) and group 4. Therapy was well tolerated.ConclusionsThis treatment based on high-dose chemotherapy and conventional radiotherapy resulted in a high survival rate in children with newly diagnosed high-risk medulloblastoma. 相似文献
994.
Linda Broer Veryan Codd Dale R Nyholt Joris Deelen Massimo Mangino Gonneke Willemsen Eva Albrecht Najaf Amin Marian Beekman Eco J C de Geus Anjali Henders Christopher P Nelson Claire J Steves Margie J Wright Anton J M de Craen Aaron Isaacs Mary Matthews Alireza Moayyeri Grant W Montgomery Ben A Oostra Jacqueline M Vink Tim D Spector P Eline Slagboom Nicholas G Martin Nilesh J Samani Cornelia M van Duijn Dorret I Boomsma 《European journal of human genetics : EJHG》2013,21(10):1163-1168
Telomere length (TL) has been associated with aging and mortality, but individual differences are also influenced by genetic factors, with previous studies reporting heritability estimates ranging from 34 to 82%. Here we investigate the heritability, mode of inheritance and the influence of parental age at birth on TL in six large, independent cohort studies with a total of 19 713 participants. The meta-analysis estimate of TL heritability was 0.70 (95% CI 0.64–0.76) and is based on a pattern of results that is highly similar for twins and other family members. We observed a stronger mother–offspring (r=0.42; P-value=3.60 × 10−61) than father–offspring correlation (r=0.33; P-value=7.01 × 10−5), and a significant positive association with paternal age at offspring birth (β=0.005; P-value=7.01 × 10−5). Interestingly, a significant and quite substantial correlation in TL between spouses (r=0.25; P-value=2.82 × 10−30) was seen, which appeared stronger in older spouse pairs (mean age ≥55 years; r=0.31; P-value=4.27 × 10−23) than in younger pairs (mean age<55 years; r=0.20; P-value=3.24 × 10−10). In summary, we find a high and very consistent heritability estimate for TL, evidence for a maternal inheritance component and a positive association with paternal age. 相似文献
995.
The epidermal growth factor receptor in human pancreatic cancer. 总被引:9,自引:0,他引:9
Nicholas R. Lemoine Christine M. Hughes Claire M. Barton Richard Poulsom Rosemary E. Jeffery Günter Klppel Peter A. Hall William J. Gullick 《The Journal of pathology》1992,166(1):7-12
The epidermal growth factor receptor (EGFR) and its ligands are thought to be important in the control of proliferation of many epithelial systems, including the exocrine pancreas. Abnormalities in expression of two of the known ligands of the EGFR, transforming growth factor alpha and epidermal growth factor, occur frequently in ductal adenocarcinoma of the human pancreas. We have examined an archival series of cases of pancreatic pathology for expression of the EGFR using the anti-EGFR antiserum 12E and found that there is almost ubiquitous overexpression of EGFR in pancreatic cancer and in chronic pancreatitis. Southern blot analysis showed no evidence of amplification or rearrangement of the EGFR gene. We conclude that an autocrine loop involving the EGFR system may be involved in the genesis of both neoplasia and reactive hyperplasia of pancreatic ductal epithelium. 相似文献
996.
Claire S. Whyte Gael B. Morrow Joanne L. Mitchell Pratima Chowdary Nicola J. Mutch 《Journal of thrombosis and haemostasis》2020,18(7):1548-1555
The global pandemic of coronavirus disease 2019 (COVID‐19) is associated with the development of acute respiratory distress syndrome (ARDS), which requires ventilation in critically ill patients. The pathophysiology of ARDS results from acute inflammation within the alveolar space and prevention of normal gas exchange. The increase in proinflammatory cytokines within the lung leads to recruitment of leukocytes, further propagating the local inflammatory response. A consistent finding in ARDS is the deposition of fibrin in the air spaces and lung parenchyma. COVID‐19 patients show elevated D‐dimers and fibrinogen. Fibrin deposits are found in the lungs of patients due to the dysregulation of the coagulation and fibrinolytic systems. Tissue factor (TF) is exposed on damaged alveolar endothelial cells and on the surface of leukocytes promoting fibrin deposition, while significantly elevated levels of plasminogen activator inhibitor 1 (PAI‐1) from lung epithelium and endothelial cells create a hypofibrinolytic state. Prophylaxis treatment of COVID‐19 patients with low molecular weight heparin (LMWH) is important to limit coagulopathy. However, to degrade pre‐existing fibrin in the lung it is essential to promote local fibrinolysis. In this review, we discuss the repurposing of fibrinolytic drugs, namely tissue‐type plasminogen activator (tPA), to treat COVID‐19 associated ARDS. tPA is an approved intravenous thrombolytic treatment, and the nebulizer form has been shown to be effective in plastic bronchitis and is currently in Phase II clinical trial. Nebulizer plasminogen activators may provide a targeted approach in COVID‐19 patients to degrade fibrin and improving oxygenation in critically ill patients. 相似文献
997.
998.
Joanna Moro Nadezda Khodorova Daniel Tom Claire Gaudichon Catherine Tardivel Thierry Berton Jean-Charles Martin Dalila Azzout-Marniche Delphine Jouan-Rimbaud Bouveresse 《Nutrients》2021,13(5)
Objective: Dietary intakes must cover protein and essential amino acid (EAA) requirements. For this purpose, different methods have been developed such as the nitrogen balance method, factorial method, or AA tracer studies. However, these methods are either invasive or imprecise, and the Food and Agriculture Organization of the United Nations (FAO, 2013) recommends new methods and, in particular, metabolomics. The aim of this study is to determine total protein/EAA requirement in the plasma and urine of growing rats. Methods: 36 weanling rats were fed with diets containing 3, 5, 8, 12, 15, and 20% protein for 3 weeks. During experimentation, urine was collected using metabolic cages, and blood from the portal vein and vena was taken at the end of the experiment. Metabolomics analyses were performed using LC-MS, and the data were analyzed with a multivariate analysis model, partial least Squares (PLS) regression, and independent component-discriminant analysis (ICDA). Each discriminant metabolite identified by PLS or ICDA was tested by one-way ANOVA to evaluate the effect of diet. Results: PLS and ICDA allowed us to identify discriminating metabolites between different diet groups. Protein deficiency led to an increase in the AA catabolism enzyme systems inducing the production of breakdown metabolites in the plasma and urine. Conclusion: These results indicate that metabolites are specific for the state of EAA deficiency and sufficiency. Some types of biomarkers such as AA degradation metabolites appear to be specific candidates for protein/EAA requirement. 相似文献
999.
Van Hout Marie Claire Haddad Patricia Aaraj Elie 《International journal of mental health and addiction》2022,20(4):2072-2085
International Journal of Mental Health and Addiction - The Middle East and North Africa (MENA) region has witnessed a slow but steady increase in the harm reduction response since 2016. It is... 相似文献
1000.
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients 下载免费PDF全文
Marcelin AG Cohen-Codar I King MS Colson P Guillevic E Descamps D Lamotte C Schneider V Ritter J Segondy M Peigue-Lafeuille H Morand-Joubert L Schmuck A Ruffault A Palmer P Chaix ML Mackiewicz V Brodard V Izopet J Cottalorda J Kohli E Chauvin JP Kempf DJ Peytavin G Calvez V 《Antimicrobial agents and chemotherapy》2005,49(5):1720-1726
The genotypic inhibitory quotient (GIQ) has been proposed as a way to integrate drug exposure and genotypic resistance to protease inhibitors and can be useful to enhance the predictivity of virologic response for boosted protease inhibitors. The aim of this study was to evaluate the predictivity of the GIQ in 116 protease inhibitor-experienced patients treated with lopinavir-ritonavir. The overall decrease in human immunodeficiency virus type 1 (HIV-1) RNA from baseline to month 6 was a median of -1.50 log(10) copies/ml and 40% of patients had plasma HIV-1 RNA below 400 copies/ml at month 6. The overall median lopinavir study-state C(min) concentration was 5,856 ng/ml. Using univariate linear regression analyses, both lopinavir GIQ and the number of baseline lopinavir mutations were highly associated with virologic response through 6 months. In the multivariate analysis, only lopinavir GIQ, baseline HIV RNA, and the number of prior protease inhibitors were significantly associated with response. When the analysis was limited to patients with more highly mutant viruses (three or more lopinavir mutations), only lopinavir GIQ remained significantly associated with virologic response. This study suggests that GIQ could be a better predictor of the virologic response than virological (genotype) or pharmacological (minimal plasma concentration) approaches used separately, especially among patients with at least three protease inhibitor resistance mutations. Therapeutic drug monitoring for patients treated by lopinavir-ritonavir would likely be most useful in patients with substantially resistant viruses. 相似文献